Nimbus Therapeutics
Nimbus Discovery: A US-based clinical-stage biotech firm specializing in metabolic, oncology, and immune-inflammatory treatments.
Founded
2009Nimbus Discovery: A US-based clinical-stage biotech firm specializing in metabolic, oncology, and immune-inflammatory treatments.
Nimbus Therapeutics, founded as Nimbus Discovery, is a clinical-stage biotechnology company focused on developing breakthrough medicines for metabolic diseases, oncology, and immune-inflammatory disorders. The company's core mission is to harness cutting-edge technologies to design highly selective small molecule therapeutics. Nimbus aims to address significant unmet medical needs through its innovative drug discovery and development processes.
Notable figures associated with Nimbus Therapeutics include its leadership team and board of directors, who bring extensive experience in biotechnology and pharmaceuticals. The company has attracted investments from prominent venture capital firms. Key achievements include advancing multiple programs into clinical trials and forming strategic partnerships to enhance their drug development capabilities. Nimbus Therapeutics has made a significant impact by progressing potential treatments for serious conditions, demonstrating its commitment to improving patient outcomes.
Companies similar to Nimbus Therapeutics include NGM Biopharmaceuticals, Nirogy Therapeutics, Complexa and Nimbus Healthcare.
Nimbus Therapeutics was founded in 2009.
Nimbus Therapeutics' headquarters is located in Cambridge, MA, US.
Nimbus Therapeutics' most recent funding round was for $210M (USD) in September 2023.
As of Sep 6, 2023, Nimbus Therapeutics has disclosed funding of $637M (USD). Undisclosed round amounts are excluded.
Nimbus Therapeutics has 112 employees as of Feb 4, 2024.
Nimbus Healthcare
